Nippon India Nifty Pharma ETF - Growth - Regular Plan

  • Previous Nav

  • Net Change on 07-06-2023

  • PersonalFN Rating

  • Category

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
NIFTY PHARMA - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India ETF Nifty 50 BeES Dec 28, 2001 15.30 24.01 12.97 0.04 12,652.85
Nippon India ETF Nifty Bank BeES May 27, 2004 27.39 28.57 10.80 0.19 6,068.51
Nippon India ETF Nifty Next 50 Junior BeES Feb 21, 2003 14.26 19.86 8.82 0.17 3,269.83
Nippon India ETF Nifty PSU Bank BeES Oct 25, 2007 62.49 43.97 6.68 0.49 1,252.99
LIC MF Nifty 50 ETF Nov 20, 2015 15.32 23.99 12.96 0.10 702.67

Fund Holdings as on 31-May-2023

  • Sun Pharmaceutical Industries Limited

  • Dr. Reddy's Laboratories Limited

  • Cipla Limited

  • Divi's Laboratories Limited

  • Lupin Limited

  • Aurobindo Pharma Limited

  • Torrent Pharmaceuticals Limited

  • Alkem Laboratories Limited

  • Laurus Labs Limited

  • Zydus Lifesciences Limited

  • Abbott India Limited

  • Biocon Limited

  • IPCA Laboratories Limited

  • Glenmark Pharmaceuticals Limited

  • Gland Pharma Limited

  • Sanofi India Limited

  • Natco Pharma Limited

  • Pfizer Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Granules India Limited

  • Triparty Repo

  • Net Current Assets

  • Cash Margin - CCIL

View More
  • Pharmaceuticals & Drugs

  • Miscellaneous

View More

Fund Manager

  • Cash

  • Equity

View More

About Nippon India Nifty Pharma ETF

Scheme Analysis

Nippon India Nifty Pharma ETF is a ETFs - Index fund and belongs to Nippon India Mutual Fund. It was launched on 06-Jul-2021 and currently has an AUM of ₹217.35 crore. Nippon India Nifty Pharma ETF is benchmarked against NIFTY 50 - TRI as primary index and NIFTY PHARMA - TRI as secondary index.

The NAV of Nippon India Nifty Pharma ETF ended up ₹0.03(0.25%)yesterday to ₹13.195.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The Nippon India Nifty Pharma ETF is managed by Mehul Dama .

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097